New Rochelle, NY, February 21, 2018-Two novel ocular hypotensive agents that have just been approved for use in humans-netarsudil and latanoprostene bunod -greatly reduce intraocular pressure, with lasting results in various animal models of glaucoma and in humans. Two articles that highlight these two breakthrough drugs, as well as cutting-edge articles on the effects of amitriptyline in dry eye disease and emerging microneedles to delivery intraocular drugs are part of a new special issue of Journal of Ocular Pharmacology and Therapeutics .

IMAGE: Journal of Ocular Pharmacology and Therapeutics is the only multidisciplinary, peer-reviewed journal providing basic and clinical research that focuses on biopharmaceuticals that have the potential to prevent, treat, and/or diagnose... view New Rochelle, NY, February 21, 2018-Two novel ocular hypotensive agents that have just been approved for use in humans -- netarsudil and latanoprostene bunod -- greatly reduce intraocular pressure, with lasting results in various animal models of glaucoma and in humans.